Epitope Profiling of SARS-CoV-2 Spike Antigen Provides a Novel Strategy for Developing ELISAs Specific for Different Spike Protein Variants in Bivalent Vaccine Formulations
This epitope-blocking strategy helped to overcome key reagent availability issues and could be applied to other projects involving related proteins.
Authors
- D. Andrew James (ORCID: https://orcid.org/0000-0002-9069-6819)
- Beata Gajewska (ORCID: https://orcid.org/0000-0003-4105-0306)
- Michael Kishko
- Luciano Ettorre
- Jason Szeto
- Trevor Williams (ORCID: https://orcid.org/0000-0003-3414-3440)
- Ali Azizi
- Shaolong Zhu (ORCID: https://orcid.org/0000-0001-9336-2016)
- Camille Houy (ORCID: https://orcid.org/0000-0001-6475-3202)
Institutions
- Global Viral (US)
- Sanofi (France) (FR)
- Sanofi (Canada) (CA)
Publication Details
- Journal
- Vaccines
- Published
- 2025-07-26
- DOI
- https://doi.org/10.3390/vaccines13080794
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- U.S. Department of Defense
- U.S. Department of Health and Human Services
- Sanofi
- Biomedical Advanced Research and Development Authority